Treatment of benign prostatic hyperplasia in patients with cardiovascular disease.
about
Cardiovascular effects of noncardiovascular drugs.Supplemental studies for cardiovascular risk assessment in safety pharmacology: a critical overview.Reversible visual loss caused by combination therapy of alfuzosin and finasteride in a patient with uveitic glaucoma.Atorvastatin attenuates testosterone-induced benign prostatic hyperplasia in rats: role of peroxisome proliferator-activated receptor-γ and cyclo-oxygenase-2.
P2860
Treatment of benign prostatic hyperplasia in patients with cardiovascular disease.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Treatment of benign prostatic hyperplasia in patients with cardiovascular disease.
@ast
Treatment of benign prostatic hyperplasia in patients with cardiovascular disease.
@en
type
label
Treatment of benign prostatic hyperplasia in patients with cardiovascular disease.
@ast
Treatment of benign prostatic hyperplasia in patients with cardiovascular disease.
@en
prefLabel
Treatment of benign prostatic hyperplasia in patients with cardiovascular disease.
@ast
Treatment of benign prostatic hyperplasia in patients with cardiovascular disease.
@en
P1433
P1476
Treatment of benign prostatic hyperplasia in patients with cardiovascular disease.
@en
P2093
Franklin C Lowe
Vincent M Santillo
P304
P356
10.2165/00002512-200623100-00003
P577
2006-01-01T00:00:00Z
P6179
1022804146